| abstract |
The present invention relates to methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects associated with certain HMG-CoA reductase inhibitors by coadministration of at least one sterol or 5α-stanol absorption inhibitor, pharmaceutically acceptable salts or solvates thereof, and at least one HMG-CoA reductase inhibitor, the latter being used sparingly in amounts insufficient to cause muscle degeneration. |